CytoDyn Pre-Tax Income 2010-2024 | CYDY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CytoDyn pre-tax income from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

CytoDyn pre-tax income from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$87.5B
Takeda Pharmaceutical (TAK)	$47.5B
Merck (MKGAF)	$24.4B
Astellas Pharma (ALPMY)	$22B
Sandoz Group AG (SDZNY)	$17.6B
Summit Therapeutics (SMMT)	$16.8B
United Therapeutics (UTHR)	$15.6B
Shionogi (SGIOY)	$13.3B
Neurocrine Biosciences (NBIX)	$12.2B
Catalent (CTLT)	$10.9B
Revolution Medicines (RVMD)	$7.7B
Orion OYJ (ORINY)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.2B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.3B
Crinetics Pharmaceuticals (CRNX)	$4.3B
Corcept Therapeutics (CORT)	$4.3B
Dyne Therapeutics (DYN)	$3.7B
PTC Therapeutics (PTCT)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
Soleno Therapeutics (SLNO)	$2B
Recursion Pharmaceuticals (RXRX)	$2B
Centessa Pharmaceuticals (CNTA)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.7B
Xencor (XNCR)	$1.7B
Harrow (HROW)	$1.6B
Cassava Sciences (SAVA)	$1.5B